Shots:
- The US FDA approved Fresenius’ Tyenne (tocilizumab-aazg) developed as a biosimilar version of Actemra (tocilizumab)
- According to the patent settlement agreement signed between Fresenius Kabi and Genentech for Tyenne, Fresenius has the license to market its tocilizumab products across the US as per the undisclosed licensing dates
- Tyenne functions as an Interleukin-6 (IL-6) receptor antagonist & has been developed using Fresenius’ analytical & manufacturing technologies for treatment of several autoimmune diseases incl. rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis & systemic juvenile idiopathic arthritis
Ref: Fresenius Kabi | Image: Fresenius Kabi| Press Release
Related News:-Celltrion Submits BLA to the US FDA for CT-P39 (Biosimilar, Xolair)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
